|
Market Closed -
Nasdaq
16:00:00 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 1.540 USD | -3.75% |
|
-13.97% | -79.08% |
| 08-31 | Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis | CI |
| 08-29 | Karyopharm Therapeutics Inc. - Special Call |
Company Valuation: Karyopharm Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 485.8 | 384.9 | 99.07 | 85.34 | 134.8 | 36.29 | - | - |
| Change | - | -20.76% | -74.26% | -13.86% | 57.91% | -73.07% | - | - |
| Enterprise Value (EV) | 426.4 | 277.1 | 99.07 | 85.34 | 134.8 | 36.29 | 36.29 | 36.29 |
| Change | - | -35.03% | -64.24% | -13.86% | 57.91% | -73.07% | 0% | 0% |
| P/E | -3.9x | -1.68x | -0.69x | -1.07x | -0.41x | -0.33x | -0.65x | -0.98x |
| PBR | -6.07x | -16.7x | - | - | - | - | - | - |
| PEG | - | -0.1x | 0x | 0x | -0x | 0x | 0x | 0x |
| Capitalization / Revenue | 2.32x | 2.45x | 0.68x | 0.59x | 0.92x | 0.27x | 0.21x | 0.11x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.27x | 0.21x | 0.11x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.37x | -0.6x | -13.7x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -24.75 | -30.3 | -18.75 | -9.45 | -17.93 | -4.7 | -2.387 | -1.575 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 209.8 | 157.1 | 146 | 145.2 | 146.1 | 135.6 | 173.6 | 332.3 |
| EBITDA | -97.48 | -141.6 | - | - | - | - | - | - |
| EBIT 1 | -98.27 | -142.2 | -129.5 | -119.4 | -90.71 | -98.75 | -60.21 | -2.649 |
| Net income 1 | -124.1 | -165.3 | -143.1 | -76.42 | -196 | -160.2 | -114.9 | -85.6 |
| Net Debt | -59.32 | -107.9 | - | - | - | - | - | - |
| Reference price 2 | 96.450 | 51.000 | 12.975 | 10.144 | 7.360 | 1.540 | 1.540 | 1.540 |
| Nbr of stocks (in thousands) | 5,037 | 7,548 | 7,636 | 8,413 | 18,310 | 22,681 | - | - |
| Announcement Date | 2/8/22 | 2/15/23 | 2/29/24 | 2/19/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.34x | - | - | - | 36.29M | |
| 18.38x | 4.26x | 10.01x | 0.49% | 79.26B | |
| -17.5x | 26.14x | -16.97x | -.--% | 58.56B | |
| 20.07x | 4.29x | 13.32x | 2.45% | 58.62B | |
| 34.59x | 11.77x | 22.57x | -.--% | 48.75B | |
| 21.02x | 4.65x | 13.25x | 0.69% | 46.32B | |
| 37.53x | 3.55x | 13.52x | -.--% | 32.12B | |
| 54.53x | 3.46x | 26.78x | -.--% | 24.77B | |
| 63.72x | 6.81x | 40.43x | -.--% | 21.5B | |
| 23.49x | 5.04x | 13.12x | -.--% | 15.97B | |
| Average | 25.55x | 7.77x | 15.11x | 0.4% | 38.59B | |
| Weighted average by Cap. | 22.21x | 8.64x | 11.59x | 0.56% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- KPTI Stock
- Valuation Karyopharm Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
